Antiangiogenic treatment for multiple CNS hemangioblastomas

Area of Science:

• Neuro-oncology
• Vascular Biology
• Oncology

Background:

• Hemangioblastomas are rare central nervous system tumors.
• Standard treatment is primarily surgical, with limited systemic options.
• No established standard of care exists beyond surgery for advanced cases.

Observation:

• Two patients with progressive, multilocular hemangioblastomas were treated.
• Bevacizumab, a vascular endothelial growth factor inhibitor, was administered.
• Patients experienced clinical benefit and radiological stabilization.

Findings:

• Bevacizumab demonstrated activity in treating hemangioblastomas.
• Tumor growth was stabilized following bevacizumab therapy.
• Clinical improvement was observed in treated patients.

Implications:

• Bevacizumab may be a viable systemic treatment option for hemangioblastomas.
• This suggests a potential therapeutic role for anti-VEGF agents in these tumors.
• Further investigation into bevacizumab for hemangioblastomas is warranted.